These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6392488)

  • 41. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
    Graham ML; Herndon JE; Casey JR; Chaffee S; Ciocci GH; Krischer JP; Kurtzberg J; Laughlin MJ; Longee DC; Olson JF; Paleologus N; Pennington CN; Friedman HS
    J Clin Oncol; 1997 May; 15(5):1814-23. PubMed ID: 9164190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan chemotherapy.
    Roodman GD; LeMaistre CF; Clark GM; Page CP; Newcomb TF; Knight WA
    Bone Marrow Transplant; 1987 Aug; 2(2):165-73. PubMed ID: 3332164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
    J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission.
    Michel G; Maraninchi D; Demeocq F; Perrimond H; Blaise D; Gaspard MH; Stoppa AM; Gastaut JA; Lepeu G; Novakovitch G
    Bone Marrow Transplant; 1988 Mar; 3(2):105-11. PubMed ID: 3048474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose melphalan allows durable engraftment of allogeneic bone marrow.
    van Besien K; Demuynck H; Lemaistre CF; Bogaerts MA; Champlin R
    Bone Marrow Transplant; 1995 Feb; 15(2):321-3. PubMed ID: 7773226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation.
    Russell JA; Selby PJ; Ruether BA; Mbidde EK; Ashley S; Zulian G; Berry J; Houwen B; Jones AR; Poon MC
    Bone Marrow Transplant; 1989 Jul; 4(4):425-9. PubMed ID: 2673463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
    Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
    J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Outcome of autologous bone marrow transplantation in 73 patients with acute leukemia].
    Han M; Feng S; Li C
    Zhonghua Xue Ye Xue Za Zhi; 1998 Aug; 19(8):422-4. PubMed ID: 11189510
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [First-line treatment of severe myelomas of the young subject by high-dose melphalan].
    Harousseau JL; Milpied N; Guilhot F; Garand R; Bourhis JH
    Presse Med; 1988 Aug 27-Sep 3; 17(29):1471-4. PubMed ID: 2971190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
    Hartmann O; Benhamou E; Beaujean F; Kalifa C; Lejars O; Patte C; Behard C; Flamant F; Thyss A; Deville A
    J Clin Oncol; 1987 Aug; 5(8):1205-11. PubMed ID: 3305792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
    Wang C; Qiao Z; Yang L; Ma L; Zhang H; Zhang J
    Chin Med J (Engl); 1996 Apr; 109(4):304-7. PubMed ID: 8758293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis.
    Imrie KR; Dubé I; Prince HM; Girouard C; Crump M; Keating A
    Bone Marrow Transplant; 1998 Feb; 21(4):395-9. PubMed ID: 9509975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone marrow transplantation following treatment with high-dose melphalan.
    Dale BM; Sage RE; Norman JE; Barber S; Kotasek D
    Transplant Proc; 1985 Apr; 17(2):1711-3. PubMed ID: 3885512
    [No Abstract]   [Full Text] [Related]  

  • 59. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
    Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.